From: The effect of calcineurin inhibitors on anthropometric measurements in kidney transplant recipients
Variables | CsA Group (n = 60) | Tac Group (n = 68) | p value |
---|---|---|---|
Transplant age (years) | 44 (20–64) | 36 (19–62) | 0.020 |
Gender (female/male) | 32/28 | 37/31 | 0.903 |
Primary etiology n (%) | |||
  Diabetes mellitus | 11 (18.3) | 1 (1.5) |  < 0.001 |
  Hypertension | 25 (41.7) | 32 (47.1) |  > 0.05 |
  Glomerulonephritis | 2 (3.3) | 11 (16.2) |  > 0.05 |
  Polycystic kidney diseases | 5 (8.3) | 3 (4.4) |  > 0.05 |
  Nephrolithiasis | 4 (6.7) | 1 (1.5) |  > 0.05 |
  Obstructive nephropathy | 2 (3.3) | 6 (8.8) |  > 0.05 |
  Amyloidosis | 1 (1.7) | 2 (2.9) |  > 0.05 |
  Unknown etiology | 10 (16.7) | 12 (17.6) |  > 0.05 |
Dialysis modality | |||
  Pre-emptive | 8 (13.3) | 14 (20.6) | 0.759 |
  Hemodialysis | 38 (63.3) | 38 (55.9) | |
  Peritoneal dialysis | 8 (13.3) | 9 (13.2) | |
  Both dialysis | 6 (10.0) | 7 (10.3) | |
Dialysis duration (month) | 66 (0:220) | 53 (0:228) | 0.851 |
Transplant type (living/deceased) | 27/33 | 34/34 | 0.319 |
Donor age (years) | 49 (22–80) | 50 (17–85) | 0.822 |
Cold ischemia time (hour) | 9.5 (1:20) | 4.5 (1:16) | 0.439 |
HLA mismatch | 3.13 ± 1.19 | 3.42 ± 1.05 | 0.144 |
Induction treatment (ATG/basiliximab) | 2/58 | 13/55 | 0.006 |
Immunosuppressive regimen n (%) | Â | Â | 0.889 |
  CsA + EC-MPS + prednisolone | 21 (35) | - |  |
  CsA + MMF + prednisolone | 39 (65) | - | |
  Tac + EC-MPS + prednisolone | - | 23 (33.8) | |
  Tac + MMF + prednisolone | - | 45 (66.2) | |
Pre-operative steroid use n (%) | 5 (8.3) | 11 (16.2) | 0.284 |
Cumulative dose of prednisolone (mg) | 11,187 ± 1,529 | 10,884 ± 1,526 | 0.289 |
Cytomegalovirus history n (%) | 17 (28.3) | 18 (26.5) | 0.845 |
BK virus n (%) | 8 (13.3) | 6 (8.8) | 0.572 |
Acute rejection n (%) | 4 (6.7) | 9 (13.2) | 0.220 |
Delayed graft function n (%) | 19 (31.7) | 17 (25) | 0.403 |